Adverse drug reactions (ADRs) are a massive burden on the NHS, and a significant cause of morbidity and mortality. When I worked on a cardiology ward, one of the more serious ADRs that occurred was severe haemorrhage associated with streptokinase. Rather than dying of a heart attack, the drug we gave to patients to improve their chances of survival would on occasion be the reason for the demise of the patient due (for example) to a cerebral haemorrhage.
The NPC recently reported on a systematic review of incidence and nature of in-hospital adverse events. The full paper is available as a free-access article at Quality and Safety in Health Care. The NPC note that the study shows:
- The median overall incidence of adverse events was 9.2% with a median percentage preventability of 43.5%.
- The median percentage attributed to medicines was 15.1% (interquartile range 11.9 to 20.4).
The NPC argue that this is in-line with a NPSA report Safety in doses: medication safety incidents in the NHS which they say showed that “between 3.5% and 9% of hospital in-patients experience harm from medicines.” However 15.1% of 9.2% is 1.39%, which is outside the range of the NPSA report. Thankfully, there is another well-conducted study due to be published later this year by the same group that published the 2004 BMJ paper on drug-related admissions to hospital. From what I have seen in presentations, the incidence is more in line with the NPSA report. It is possible that studies which are primarily focused on drug therapy have greater sensitivity to adverse effects of drugs than those which attempt to catch all patient-care events.
Another point worth discussing about the NPC blog post their view on the impact of the study:
The Impact
Adverse events related to medicines are a serious health issue. They cause levels of mortality higher than more high-profile health problems such as breast cancer or AIDS. In addition to the harm caused to individual patients, they also place a significant burden on healthcare resources.
The source from this comment arises from the report To Err is Human, an influential, and often cited, IOM report from 2000. The executive summary uses this comparison:
More people die in a given year as a result of medical errors than from motor vehicle accidents (43,458), breast cancer (42,297), or AIDS (16,516).
I’ve used similar statements myself in order to shock health care professionals into accepting the burden of ADRs as important and worthy of their consideration, but these sort of statements can also feed into some of the more deranged, but not totally uncommon, rants about Big Pharma. Here’s a relatively extreme example from JABS, the UK’s leading anti-vaccination site commonly linked to by the BBC:
big pharma and bad doctors have killed more people than wars in the last 50 years.
For gods sake what more corruption, cover ups and evil does big pharma have to do beside kill a million each year so these sick trolls will stop acting as as shills for them.
Who would you listen to , a mad sick corrupt troll who showns sociopathic tendanicies who thinks its fine for big pharma to commit genocide or real non corporate doctors and scientists who actually care about humanity and big pharma genocide and corruption.
I think sensible discussions about the harms of medicines need to avoid feeding into this meme, and documents like To Err is Human can unfortunately be used by opponents of evidence-based medicine to attack the use of prescribed drugs. What’s missing is the difference between breast cancer and prescribed drugs.
The difference between breast cancer, and the adverse effects of drugs, is that drugs have beneficial effects that, on balance, outweigh the risks they pose to society. For individual drugs when the risks are found to outweigh the benefits, then action is taken such as withdrawal of the drug. There is no corresponding benefit to having AIDS or breast cancer.
Every day individual patients make decisions about risk-benefits when they chose to take a medicine or not. Of course, many could be better informed about that risk-benefit balance, but overall the majority chose to accept the risks for the benefit they will receive. Sometimes patients will accept more risks than regulators think they should. Medicines are more like cars. There is a benefit from the mobility and personal freedom that cars give individuals, which seem to make death in car accidents relatively less important than knife crime, despite the massively higher numbers of deaths in car accidents (I accept the issue of intent makes a difference in this area).
The issue of preventability is also difficult. Some drugs increase the odds of experiencing an adverse event. Not all events will therefore be avoidable. Aspirin increases the risk of a gastric bleed. So not all gastric bleeds could have been avoided if aspirin had not been prescribed.
There is also the issue of monitoring: Coleman et al’s paper in the BJCP neatly explains the lack of evidence for effective methods of monitoring for harms of treatment. Here’s another cardiology example, which I also regularly saw, which Coleman uses to illustrate the difficulties of devising monitoring periods:
The incidence of hyperkalaemia in patients treated with spironolactone for heart failure seems much greater in practice than in the randomized controlled trial that showed the value of the treatment. This seems unlikely to be simply a problem of monitoring. In general terms, patients in clinical practice are sicker and less frequently reviewed than in clinical trials and therefore it is not surprising that in many examples the rate of adverse effects is higher in actual use when compared with the rates seen in the trials. Real patients may also be less likely to adhere to a stringent monitoring scheme, or more likely to have concurrent ill health that increases the chances of finding an abnormal result that is not due to the adverse reaction, or older than trial patients, and perhaps as a consequence more rapidly susceptible to the adverse drug reaction, so that the time between a reaction first being observable and it causing irreversible damage may be shorter. It raises the question of how to devise safe monitoring schemes that will remain effective when treatments move from clinical trials to general use.
So preventability can be in the eye of the beholder, and that eye is often trained on the events using a retrospectoscope, armed with more information, and time, than the clinician making the decision that led to the adverse effect.
And some adverse reactions are not preventable. Take streptokinase, discussed at the start of this post. Even with a perfect diagnosis, and evidence-based treatment, fatal adverse effects can occur. However, on balance streptokinase saved more than it lost, and this should be acknowledged when talking about the harms of medicines.


